The FDA released draft guidance that, in certain situations, would allow biosimilar developers to rely on comparator data generated outside the U.S., potentially lowering the cost and time required for comparative clinical testing. The agency framed the change as a pragmatic step to expand biosimilar competition while maintaining standards for analytical and clinical comparability. Industry observers note the shift could cut development expenses substantially and accelerate biosimilar approvals, especially for complex biologics where clinical comparators dominate cost and timeline. Europe’s more mature biosimilar market was highlighted as a precedent for relying on foreign comparator data. If finalized, the guidance could unlock broader biosimilar entry across therapeutic areas, including oncology and immunology, but companies will still face manufacturing, interchangeability, and patent‑challenge hurdles before achieving widespread market access.